TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 196 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $17,267,000 | +67.3% | 229,456 | -40.3% | 0.00% | +100.0% |
| Q1 2022 | $10,323,000 | -32.2% | 384,426 | +20.4% | 0.00% | -50.0% |
| Q4 2021 | $15,227,000 | -14.2% | 319,214 | +19.5% | 0.00% | 0.0% |
| Q3 2021 | $17,745,000 | -19.8% | 267,131 | -5.8% | 0.00% | -33.3% |
| Q2 2021 | $22,136,000 | +661.7% | 283,717 | +823.5% | 0.00% | – |
| Q1 2021 | $2,906,000 | -50.0% | 30,723 | -35.6% | 0.00% | -100.0% |
| Q4 2020 | $5,815,000 | +109.2% | 47,719 | +52.0% | 0.00% | – |
| Q3 2020 | $2,780,000 | +113.2% | 31,401 | +55.6% | 0.00% | – |
| Q2 2020 | $1,304,000 | -11.8% | 20,185 | -39.1% | 0.00% | – |
| Q1 2020 | $1,479,000 | +12.0% | 33,118 | +56.2% | 0.00% | – |
| Q4 2019 | $1,321,000 | +1511.0% | 21,208 | +874.2% | 0.00% | – |
| Q3 2019 | $82,000 | +15.5% | 2,177 | +19.4% | 0.00% | – |
| Q2 2019 | $71,000 | – | 1,824 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |